Trio Medicines Ltd.
15
0
0
13
Key Highlights
Risk & Performance
Pipeline Risk Assessment
Pipeline Risk Assessment
Based on historical performance
Moderate Risk
Score: 45/100
13.3%
2 terminated/withdrawn out of 15 trials
86.7%
+0.2% vs industry average
0%
0 trials in Phase 3/4
23%
3 of 13 completed trials have results
Key Signals
Enrollment Performance
Analytics
Activity Timeline
Global Presence
Clinical Trials (15)
Selective β2-AR Antagonism in Asthma
Role: lead
Trial of a Gastrin Receptor Antagonist in Barrett's Esophagus
Role: collaborator
YF476 in Barrett's Esophagus
Role: lead
YF476 and Type II Gastric Carcinoids
Role: lead
YF476 and Type I Gastric Carcinoids
Role: lead
Effect of Netazepide on Omeprazole-induced Changes in Chromogranin A and Gastrin
Role: lead
YF476 and Type I Gastric Carcinoids (Norway)
Role: lead
Avonex®: Safety, Blood Levels and Effects
Role: lead
Effects of YF476 and Rabeprazole on Gastric Function
Role: lead
Effect of Single Doses of YF476 on Stomach Acidity
Role: lead
Effect of Repeated Doses of YF476 on Stomach Acidity
Role: lead
Effect of Repeated Doses of YF476, Omeprazole and Placebo on Stomach Acidity in Healthy Volunteers
Role: lead
Effect of 5, 10 or 25 mg of YF476 Daily for 14 Days on Stomach Acidity in Healthy Volunteers
Role: lead
Effect of Single Doses of YF476 on Stomach Acidity Compared With Ranitidine and Placebo in Fasted and Fed States
Role: lead
Safety, Tolerability and Pharmacokinetics of Single Rising Doses of YF476, a Gastrin Antagonist, in Healthy Men
Role: lead
All 15 trials loaded